Xiaorong Lai1, Qiumei Dong1, Fei Xu1, Sipei Wu2, Dongyang Yang1, Chao Liu3, Ying Li1, Zijun Li4, Dong Ma1. 1. Department of Internal Medicine-Oncology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. 2. Guangdong Lung Cancer Institute; Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. 3. Department of Pathology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. 4. Department of Gastroenterology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Abstract
BACKGROUND: The proto-oncogene c-MET (mesenchymal-epithelial transition factor gene) plays a critical role in cellular proliferation, survival, migration, and invasion in cancers. The aim of this study is to explore the relationship between c-MET expression and the clinicopathological characteristics of colorectal cancer (CRC) patients. METHODS: A total of 337 enrolled patients were collected in present study. Here, the c-MET and EGFR expression were detected by immunohistochemistry (IHC). The mutational statuses of KRAS in exons 2, 3, and 4, NRAS in exons 2, 3, and 4, and BRAF in exon 15 from formalin-fixed sections were detected by direct DNA sequencing. RESULTS: Our results showed that high c-MET expression was significantly associated with tumor perineural invasion (P=0.007) and gender (P=0.016). High level c-MET expression (c-MET-high) in the primary tumors was observed in 68.2% of patients. In the 337 enrolled patients, 43.2% of patients had KRAS mutations, 3.3% of patients had NRAS mutations, and 4.7% of patients had BRAF mutations. However, KRAS, NRAS, and BRAF gene mutations had no association with c-MET protein levels in primary tumors. Additionally, c-MET protein expression had a strong correlation with EGFR expression (P=0.002). The survival time was not significantly longer for patients with c-MET-high primary tumors than for those with c-MET-low primary tumors. CONCLUSIONS: c-MET immunohistochemistry was significantly higher in primary tumors with perineural invasion, female gender, and EGFR high expression. However, c-MET-high in the primary tumors was not significantly associated with longer survival compared with c-MET-low tumors. Further studies are required to investigate c-MET as potential molecular marker of progression and to test the possibility of its incorporation as a new therapeutic target. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
BACKGROUND: The proto-oncogene c-MET (mesenchymal-epithelial transition factor gene) plays a critical role in cellular proliferation, survival, migration, and invasion in cancers. The aim of this study is to explore the relationship between c-MET expression and the clinicopathological characteristics of colorectal cancer (CRC) patients. METHODS: A total of 337 enrolled patients were collected in present study. Here, the c-MET and EGFR expression were detected by immunohistochemistry (IHC). The mutational statuses of KRAS in exons 2, 3, and 4, NRAS in exons 2, 3, and 4, and BRAF in exon 15 from formalin-fixed sections were detected by direct DNA sequencing. RESULTS: Our results showed that high c-MET expression was significantly associated with tumor perineural invasion (P=0.007) and gender (P=0.016). High level c-MET expression (c-MET-high) in the primary tumors was observed in 68.2% of patients. In the 337 enrolled patients, 43.2% of patients had KRAS mutations, 3.3% of patients had NRAS mutations, and 4.7% of patients had BRAF mutations. However, KRAS, NRAS, and BRAF gene mutations had no association with c-MET protein levels in primary tumors. Additionally, c-MET protein expression had a strong correlation with EGFR expression (P=0.002). The survival time was not significantly longer for patients with c-MET-high primary tumors than for those with c-MET-low primary tumors. CONCLUSIONS: c-MET immunohistochemistry was significantly higher in primary tumors with perineural invasion, female gender, and EGFR high expression. However, c-MET-high in the primary tumors was not significantly associated with longer survival compared with c-MET-low tumors. Further studies are required to investigate c-MET as potential molecular marker of progression and to test the possibility of its incorporation as a new therapeutic target. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
Authors: Udai S Kammula; Eleanor J Kuntz; Todd D Francone; Zhaoshi Zeng; Jinru Shia; Ron G Landmann; Philip B Paty; Martin R Weiser Journal: Cancer Lett Date: 2006-09-01 Impact factor: 8.679
Authors: Patrick C Ma; Maria S Tretiakova; Alexander C MacKinnon; Nithya Ramnath; Candace Johnson; Sascha Dietrich; Tanguy Seiwert; James G Christensen; Ramasamy Jagadeeswaran; Thomas Krausz; Everett E Vokes; Aliya N Husain; Ravi Salgia Journal: Genes Chromosomes Cancer Date: 2008-12 Impact factor: 5.006
Authors: Zhao-Shi Zeng; Martin R Weiser; Eleanor Kuntz; Chin-Tung Chen; Sajid A Khan; Ann Forslund; Garrett M Nash; Mark Gimbel; Yuka Yamaguchi; Alfred T Culliford; Matthew D'Alessio; Francis Barany; Philip B Paty Journal: Cancer Lett Date: 2008-04-18 Impact factor: 8.679
Authors: Gemma R Armstrong; Mohammed Ibrahim Khot; Jim P Tiernan; Nick P West; Sarah L Perry; Tom I Maisey; Thomas A Hughes; David G Jayne Journal: Int J Exp Pathol Date: 2021-05-05 Impact factor: 1.925